Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells

Molecular Cancer Therapeutics

Volumn 3, Issue 12, 2004, Pages 1615-1621

  Marciniak, Dorota J ^a   Rishi, Arun K ^a   Sarkar, Fazlul H ^a   Majumdar, Adhip P N ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR RELATED PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDE DERIVATIVE; PROTEIN KINASE B; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

APOPTOSIS; GLYCOPROTEINS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 12344334586     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Landis SH, Murray T, Bolden Wingo PA. Cancer statistics 1999. Cancer 1999;49:8-31.
2. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-8.
3. Tillostson JK, Rose DP. Endogenous secretion of epidermal growth factor peptides stimulates growth of DU145 prostate cancer cells. Cancer Lett 1991;60:109-12.
4. Davies P, Eaton CL, France TD, Philips ME. Growth factor receptors and oncogene expression in prostate cells. Am J Clin Oncol 1988;11:S1-7.
5. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54: 5474-8.
6. Sherwood ER, Van Dongen JL, Wood CG, Jiao S, Kozlowski JM, Lee C. Epidermal growth factor receptors activation in androgen-independent but not androgen stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998;77:855-61.
7. Leav I, McNeal JE, Ziar J, Alroy J. The localization of transforming growth factor α and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions. Hum Pathol 1998;29:668-75.
8. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JG. Expression of mRNA for epidermal growth factor, transforming growth factor-α and their receptor on human prostate tissue and cell lines. Mol Cell Biochem 1993;126:151-8.
9. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-α and epidermal growth factor receptor in human prostate tissues. J Urol 1994;152:2120-4.
10. Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1:545-50.
11. Morris GL, Dodd JG. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 1990;143:1272-4.
12. Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 1996;77:627-33.
13. Jenster G. The role of androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999;26:407-21.
14. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-23.
15. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effect of insulin epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin but not androgen or normal rat prostate epithelial cells in serum free primary cell culture. Cancer Res 1984;48:1998-2010.
16. Lee HL, Pienta KJ, Kim WJ, Cooper C. The effect of bone associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int J Oncol 2003;22:921-6.
17. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-73.
18. Gibbs JB. Anticancer drugs targets: growth factors and growth factors signaling. J Clin Invest 2000;105:9-13.
19. Yu Y, Rishi A, Turner JR, et al. Cloning of the novel EGFR-related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol 2001;280:C1083-9.
20. Marciniak DJ, Moragoda L, Mohammad RM, et al. Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology 2003;124:1337-47.
21. Majumdar APN, Tureaud J, Relan NK, et al. Increased expression of pp60c-src in gastric mucosa of aged rats. J Gerontol Biol Sci 1994;49: B110-6.
22. Majumdar APN, Goldenring JR. Localization and significance of pp55, a gastric mucosal membrane protein with tyrosine kinase activity. Am J Physiol 1998;274:G863-70.
23. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O, Majumdar APN. Folic acid mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2004;287: G541-6.
24. Barnard JH, Beauchamp RD, Russell WE, Dubois RN. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995;108:564-80.
25. Romashkova JA, Makarov SS. NF-κB is target of AKT in anti-apoptotic PDGF signaling. Nature 1999;401:86-90.
26. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003;22:4702-9.
27. Pages G, Lenormand P, L'Allemanin G, Meloche JC, Poyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 1993;90:8319-23.
28. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78.
29. Candena DL, Gill GN. Receptor tyrosine kinases. FASEB J 1992;6: 2332-7.
30. Glenney JR. Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases. Biochim Biophys Acta 1992;1134: 113-27.
31. Salomon DS, Brandt R, Ciardielllo F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
32. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
33. Baselga J, Meldelsohn J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J Mammary Gland Biol Neoplasia 1997;2:165-74.
34. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
35. Relan NK, Saeed A, Ponduri K, Fligiel SEG, Dutta S, Majumdar APN. Identification and evaluation of the role of endogenous tyrosine kinases in azoxymethane induction of proliferative processes in the colonic mucosa of rats. Biochim Biophys Acta 1995;1244:368-76.
36. Coffey R Jr, Shipley GD, Moses HL. Production of transforming growth factors by human colon cancer cell lines. Cancer Res 1986;46: 1164-9.
37. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95:851-67.
38. Ritter CA, Arteago CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30:3-11.
39. Levi E, Mohammad R, Kodali U, et al. EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. Anticancer Res 2004;24:885-92.
40. Majumdar APN, Du J, Hatfield J, et al. Expression of EGR-receptor related protein (ERRP) decreases during aging and carcinogenesis. Dig Dis Sci 2003;48:856-64.